
Quarterly report 2025-Q3
added 11-04-2025
InfuSystem Holdings Revenue 2011-2026 | INFU
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue InfuSystem Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 M | 102 M | 97.4 M | 81.1 M | 67.1 M | 71.1 M | 70.5 M | 72.1 M | 66.5 M | 62.3 M | 58.8 M | 54.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 M | 54.6 M | 76.2 M |
Quarterly Revenue InfuSystem Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.5 M | 36 M | 34.7 M | - | 35.3 M | 33.7 M | 32 M | - | 31.9 M | 31.7 M | 30.4 M | - | 27.3 M | 27 M | 26.8 M | - | 26.6 M | 24.8 M | 24.5 M | - | 25.1 M | 26 M | 21.6 M | - | 21.5 M | 19.7 M | 18.2 M | - | 16.7 M | 16.4 M | 16.5 M | - | 17.6 M | 16.9 M | 17.7 M | - | 17.2 M | 18.1 M | 18.3 M | 18.7 M | 18.3 M | 16.9 M | 16.7 M | - | 16.6 M | 16.4 M | 17.2 M | - | 15.7 M | 14.7 M | 14.7 M | - | 14.2 M | 14.1 M | 14.3 M | - | 14.5 M | 13.1 M | 13 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.5 M | 13 M | 21.6 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
11.2 B | $ 16.47 | -1.08 % | $ 8.45 B | ||
|
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | ||
|
Alcon
ALC
|
10.4 B | $ 74.46 | -0.25 % | $ 40.4 B | ||
|
The Cooper Companies
COO
|
4.09 B | $ 69.5 | -1.13 % | $ 13.8 B | ||
|
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | ||
|
electroCore
ECOR
|
32 M | $ 7.04 | - | $ 59.7 K | ||
|
Ekso Bionics Holdings
EKSO
|
12.8 M | $ 9.6 | -1.54 % | $ 23.3 M | ||
|
BioLife Solutions
BLFS
|
82.3 M | $ 19.0 | -1.4 % | $ 875 M | ||
|
AtriCure
ATRC
|
535 M | $ 28.76 | -1.47 % | $ 1.37 B | ||
|
Glaukos Corporation
GKOS
|
315 M | $ 115.08 | -1.41 % | $ 5.57 B | ||
|
Haemonetics Corporation
HAE
|
1.36 B | $ 58.1 | -0.54 % | $ 2.92 B | ||
|
Harvard Bioscience
HBIO
|
86.6 M | $ 5.53 | - | $ 245 M | ||
|
iRhythm Technologies
IRTC
|
747 M | $ 115.36 | -1.59 % | $ 3.69 B | ||
|
Repro Med Systems
KRMD
|
41.1 M | $ 4.25 | -0.23 % | $ 196 M | ||
|
Masimo Corporation
MASI
|
2.09 B | $ 178.34 | -0.08 % | $ 9.51 B | ||
|
Microbot Medical
MBOT
|
117 K | $ 2.32 | -1.91 % | $ 106 M | ||
|
Milestone Scientific
MLSS
|
8.97 M | $ 0.29 | - | $ 23.8 M | ||
|
Envista Holdings Corporation
NVST
|
2.72 B | $ 25.51 | -1.22 % | $ 4.29 B | ||
|
Pro-Dex
PDEX
|
66.6 M | $ 48.53 | - | $ 160 M | ||
|
ICU Medical
ICUI
|
2.23 B | $ 121.67 | -1.08 % | $ 3 B | ||
|
ResMed
RMD
|
3.58 B | $ 224.04 | -0.34 % | $ 32.7 B | ||
|
Retractable Technologies
RVP
|
38.3 M | $ 0.71 | -0.07 % | $ 21.3 M | ||
|
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
10.1 B | $ 449.17 | -0.75 % | $ 160 B | ||
|
STAAR Surgical Company
STAA
|
239 M | $ 21.44 | 2.29 % | $ 1.06 B | ||
|
Stereotaxis
STXS
|
32.4 M | $ 1.85 | -1.86 % | $ 168 M | ||
|
LeMaitre Vascular
LMAT
|
250 M | $ 109.83 | 0.61 % | $ 2.49 B | ||
|
Teleflex Incorporated
TFX
|
569 M | $ 114.86 | -0.2 % | $ 5.13 B | ||
|
Merit Medical Systems
MMSI
|
1.52 B | $ 66.72 | -1.61 % | $ 3.95 B | ||
|
Utah Medical Products
UTMD
|
9.04 M | $ 63.75 | 1.3 % | $ 207 M | ||
|
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
350 K | $ 21.68 | -5.49 % | $ 1.46 B | ||
|
West Pharmaceutical Services
WST
|
3.07 B | $ 258.0 | 0.4 % | $ 18.7 B | ||
|
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 11.45 | -1.63 % | $ 2.28 B | ||
|
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | ||
|
STERIS plc
STE
|
5.46 B | $ 219.18 | -0.37 % | $ 21.6 B | ||
|
AngioDynamics
ANGO
|
292 M | $ 9.51 | -3.35 % | $ 389 M | ||
|
Becton, Dickinson and Company
BDX
|
21.8 B | $ 154.32 | -0.59 % | $ 44.4 B | ||
|
Nephros
NEPH
|
14.2 M | $ 2.81 | -1.75 % | $ 29.2 M | ||
|
OraSure Technologies
OSUR
|
115 M | $ 3.05 | -1.14 % | $ 224 M | ||
|
Repligen Corporation
RGEN
|
632 M | $ 116.46 | -0.42 % | $ 6.49 M |